title: Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.
abstract: A Phase II trial of 75 mCi/m2 131I-anti-TAG-72 high-affinity antibody CC49 was studied in 15 patients with hormone-resistant metastatic prostate cancer.
  
  
  METHODS
  Patients had adequate renal, liver and hematopoietic function. No previous cytotoxic chemotherapy was allowed and previous radiation was limited to 20% of the active bone marrow.
  
  
  RESULTS
  No acute adverse reactions occurred, but all patients had evidence of an immune response to CC49 by 4 wk. Six of 10 symptomatic patients had bone pain relief, but no patients met the radiographic or PSA criteria for objective response. Positive imaging of bone and/or soft-tissue lesions was noted for 13 of the 15 patients.
  
  
  CONCLUSIONS
  CC49 had a high frequency of tumor localization with evidence of anti-tumor effects (pain relief).
authors.affiliation: Department of Radiation Oncology, University of Alabama at Birmingham 35294-3300.
authors.forename: R F
authors.initials: RF
authors.lastname: Meredith
authors.forename: A J
authors.initials: AJ
authors.lastname: Bueschen
authors.forename: M B
authors.initials: MB
authors.lastname: Khazaeli
authors.forename: W E
authors.initials: WE
authors.lastname: Plott
authors.forename: W E
authors.initials: WE
authors.lastname: Grizzle
authors.forename: R H
authors.initials: RH
authors.lastname: Wheeler
authors.forename: J
authors.initials: J
authors.lastname: Schlom
authors.forename: C D
authors.initials: CD
authors.lastname: Russell
authors.forename: T
authors.initials: T
authors.lastname: Liu
authors.forename: A F
authors.initials: AF
authors.lastname: LoBuglio
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary*; D000368:Aged; D000369:Aged, 80 and over; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000473:pathology*; D016499:Radioimmunotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D015899:Tomography, Emission-Computed, Single-Photon